title: Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras.
abstract: X-linked severe combined immunodeficiency (XSCID) is caused by mutations of the common gamma chain of cytokine receptors, gamma(c). Because bone marrow transplantation (BMT) for XSCID does not provide complete immune reconstitution for many patients and because of the natural selective advantage conferred on lymphoid progenitors by the expression of normal gamma(c), XSCID is a good candidate disease for therapeutic retroviral gene transfer to hematopoietic stem cells. We studied XSCID patients who have persistent defects in B-cell and/or combined B- and T-cell function despite having received T cell-depleted haploidentical BMT. We compared transduction of autologous B-cell lines and granulocyte colony-stimulating factor-mobilized peripheral CD34(+) cells from these patients using an MFGS retrovirus vector containing the gamma(c) gene IL2RG pseudotyped with amphotropic, gibbon ape leukemia virus, or RD114 envelopes. Transduced B-cell lines and peripheral CD34(+) cells demonstrated provirus integration and new cell-surface gamma(c) expression. The chimeric sheep model was exploited to test development of XSCID CD34(+) cells into mature myeloid and lymphoid lineages. Transduced and untransduced XSCID CD34(+) cells injected into developing sheep fetuses gave rise to myeloid cells. However, only transduced gamma progenitors from XSCID patients developed into T and B cells. These results suggest that gene transfer to autologous peripheral CD34(+) cells using MFGS-gc retrovirus may benefit XSCID patients with persistent T- and B-cell deficits despite prior BMT.
authors.affiliation: National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Tsai
authors.forename: Harry L
authors.initials: HL
authors.lastname: Malech
authors.forename: Martha R
authors.initials: MR
authors.lastname: Kirby
authors.forename: Amy P
authors.initials: AP
authors.lastname: Hsu
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Seidel
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Porada
authors.forename: Esmail D
authors.initials: ED
authors.lastname: Zanjani
authors.forename: David M
authors.initials: DM
authors.lastname: Bodine
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Puck
mesh_terms: D000818:Animals; D018952:Antigens, CD34; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D019070:Cell Lineage; D002648:Child; D002675:Child, Preschool; D008040:Genetic Linkage; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D007223:Infant; D023421:Models, Animal; D009154:Mutation; D021122:Protein Subunits; D015375:Receptors, Interleukin-2 / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use; D012190:Retroviridae / Q000235:genetics; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012756:Sheep; D013601:T-Lymphocytes / Q000166:cytology; D014161:Transduction, Genetic / Q000379:methods; D018183:Transplantation Chimera; D014960:X Chromosome
chemical_list: D018952:Antigens, CD34; D021122:Protein Subunits; D015375:Receptors, Interleukin-2